Tumor location determines tissue-specific recruitment of tumor-associated macrophages and antibody-dependent immunotherapy response

Science Immunology

Volumn 2, Issue 7, 2017, Pages

  Lehmann, Birgit ^a   Biburger, Markus ^a   Brückner, Christin ^a   Ipsen Escobedo, Andrea ^a   Gordan, Sina ^a   Lehmann, Christian ^b   Voehringer, David ^b   Winkler, Thomas ^a   Schaft, Niels ^b   Dudziak, Diana ^b   Sirbu, Horia ^b   Weber, Georg F ^b   Nimmerjahn, Falk ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85019210402     PISSN: None     EISSN: 24709468     Source Type: Journal    
DOI: 10.1126/sciimmunol.aah6413     Document Type: Article

References (64)

1. J. Galon, H. K. Angell, D. Bedognetti, F. M. Marincola, The continuum of cancer immunosurveillance: Prognostic, predictive, and mechanistic signatures. Immunity 39, 11–26 (2013).
2. T. F. Gajewski, H. Schreiber, Y.-X. Fu, Innate and adaptive immune cells in the tumor microenvironment. Nat. Immunol. 14, 1014–1022 (2013).
3. L. Bingle, N. J. Brown, C. E. Lewis, The role of tumour-associated macrophages in tumour progression: Implications for new anticancer therapies. J. Pathol. 196, 254–265 (2002).
4. T. Kitamura, B.-Z. Qian, J. W. Pollard, Immune cell promotion of metastasis. Nat. Rev. Immunol. 15, 73–86 (2015).
5. D. I. Gabrilovich, S. Ostrand-Rosenberg, V. Bronte, Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12, 253–268 (2012).
6. D. T. Graves, Y. L. Jiang, M. J. Williamson, A. J. Valente, Identification of monocyte chemotactic activity produced by malignant cells. Science 245, 1490–1493 (1989).
7. R. P. Negus, G. W. Stamp, M. G. Relf, F. Burke, S. T. Malik, S. Bernasconi, P. Allavena, S. Sozzani, A. Mantovani, F. R. Balkwill, The detection and localization of monocyte chemoattractant protein-1 (MCP-1) in human ovarian cancer. J. Clin. Invest. 95, 2391–2396 (1995).
8. M. P. Wong, K. N. Cheung, S. T. Yuen, K. H. Fu, A. S. Y. Chan, S. Y. Leung, L. P. Chung, Monocyte chemoattractant protein-1 (MCP-1) expression in primary lymphoepithelioma-like carcinomas (LELCs) of the lung. J. Pathol. 186, 372–377 (1998).
9. R. Noy, J. W. Pollard, Tumor-associated macrophages: From mechanisms to therapy. Immunity 41, 49–61 (2014).
10. T. Kitamura, B.-Z. Qian, D. Soong, L. Cassetta, R. Noy, G. Sugano, Y. Kato, J. Li, J. W. Pollard, CCL2-induced chemokine cascade promotes breast cancer metastasis by enhancing retention of metastasis-associated macrophages. J. Exp. Med. 212, 1043–1059 (2015).
11. B.-Z. Qian, J. Li, H. Zhang, T. Kitamura, J. Zhang, L. R. Campion, E. A. Kaiser, L. A. Snyder, J. W. Pollard, CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 475, 222–225 (2011).
12. S. M. Scholl, C. Pallud, F. Beuvon, K. Hacene, E. R. Stanley, L. Rohrschneider, R. Tang, P. Pouillart, R. Lidereau, Anti-colony-stimulating factor-1 antibody staining in primary breast adenocarcinomas correlates with marked inflammatory cell infiltrates and prognosis. J. Natl. Cancer Inst. 86, 120–126 (1994).
13. D. Hanahan, R. A. Weinberg, Hallmarks of cancer: The next generation. Cell 144, 646–674 (2011).
14. E. B. Belai, C. E. de Oliveira, T. H. Gasparoto, R. N. Ramos, S. A. Torres, G. P. Garlet, K. A. Cavassani, J. S. Silva, A. P. Campanelli, PD-1 blockage delays murine squamous cell carcinoma development. Carcinogenesis 35, 424–431 (2014).
15. J. Duraiswamy, G. J. Freeman, G. Coukos, Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer. Cancer Res. 73, 6900–6912 (2013).
16. P. Andreu, M. Johansson, N. I. Affara, F. Pucci, T. Tan, S. Junankar, L. Korets, J. Lam, D. Tawfik, D. G. DeNardo, L. Naldini, K. E. de Visser, M. De Palma, L. M. Coussens, FcRg activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell 17, 121–134 (2010).
17. C. H. Ries, M. A. Cannarile, S. Hoves, J. Benz, K. Wartha, V. Runza, F. Rey-Giraud, L. P. Pradel, F. Feuerhake, I. Klaman, T. Jones, U. Jucknischke, S. Scheiblich, K. Kaluza, I. H. Gorr, A. Walz, K. Abiraj, P. A. Cassier, A. Sica, C. Gomez-Roca, K. E. de Visser, A. Italiano, C. Le Tourneau, J.-P. Delord, H. Levitsky, J.-Y. Blay, D. Rüttinger, Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell 25, 846–859 (2014).
18. M. A. Cannarile, C. H. Ries, S. Hoves, D. Rüttinger, Targeting tumor-associated macrophages in cancer therapy and understanding their complexity. OncoImmunology 3, e955356 (2014).
19. R. A. Franklin, W. Liao, A. Sarkar, M. V. Kim, M. R. Bivona, K. Liu, E. G. Pamer, M. O. Li, The cellular and molecular origin of tumor-associated macrophages. Science 344, 921–925 (2014).
20. R. N. Hanna, C. Cekic, D. Sag, R. Tacke, G. D. Thomas, H. Nowyhed, E. Herrley, N. Rasquinha, S. McArdle, R. Wu, E. Peluso, D. Metzger, H. Ichinose, I. Shaked, G. Chodaczek, S. K. Biswas, C. C. Hedrick, Patrolling monocytes control tumor metastasis to the lung. Science 350, 985–990 (2015).
21. S. Shimura, G. Yang, S. Ebara, T. M. Wheeler, A. Frolov, T. C. Thompson, Reduced infiltration of tumor-associated macrophages in human prostate cancer: Association with cancer progression. Cancer Res. 60, 5857–5861 (2000).
22. T. Migita, E. Sato, K. Saito, T. Mizoi, K.-I. Shiiba, S. Matsuno, H. Nagura, H. Ohtani, Differing expression of MMPs-1 and -9 and urokinase receptor between diffuse- and intestinal-type gastric carcinoma. Int. J. Cancer 84, 74–79 (1999).
23. J. M. Reichert, C. J. Rosensweig, L. B. Faden, M. C. Dewitz, Monoclonal antibody successes in the clinic. Nat. Biotechnol. 23, 1073–1078 (2005).
24. M. J. Glennie, J. G. J. van de Winkel, Renaissance of cancer therapeutic antibodies. Drug Discov. Today 8, 503–510 (2003).
25. I. Melero, S. Hervas-Stubbs, M. Glennie, D. M. Pardoll, L. Chen, Immunostimulatory monoclonal antibodies for cancer therapy. Nat. Rev. Cancer 7, 95–106 (2007).
26. F. Nimmerjahn, S. Gordan, A. Lux, FcgR dependent mechanisms of cytotoxic, agonistic, and neutralizing antibody activities. Trends Immunol. 36, 325–336 (2015).
27. A. Pincetic, S. Bournazos, D. J. DiLillo, J. Maamary, T. T. Wang, R. Dahan, B.-M. Fiebiger, J. V. Ravetch, Type I and type II Fc receptors regulate innate and adaptive immunity. Nat. Immunol. 15, 707–716 (2014).
28. S. A. Beers, M. S. Cragg, M. J. Glennie, Complement: Help or hindrance? Blood 114, 5567–5568 (2009).
29. P. M. Hogarth, G. A. Pietersz, Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond. Nat. Rev. Drug Discov. 11, 311–331 (2012).
30. M. Biburger, A. Lux, F. Nimmerjahn, How immunoglobulin G antibodies kill target cells: Revisiting an old paradigm. Adv. Immunol. 124, 67–94 (2014).
31. S. A. Beers, R. R. French, H. T. C. Chan, S. H. Lim, T. C. Jarrett, R. M. Vidal, S. S. Wijayaweera, S. V. Dixon, H. Kim, K. L. Cox, J. P. Kerr, D. A. Johnston, P. W. M. Johnson, J. S. Verbeek, M. J. Glennie, M. S. Cragg, Antigenic modulation limits the efficacy of anti-CD20 antibodies: Implications for antibody selection. Blood 115, 5191–5201 (2010).
32. M. Biburger, S. Aschermann, I. Schwab, A. Lux, H. Albert, H. Danzer, M. Woigk, D. Dudziak, F. Nimmerjahn, Monocyte subsets responsible for immunoglobulin G-dependent effector functions in vivo. Immunity 35, 932–944 (2011).
33. V. Minard-Colin, Y. Xiu, J. C. Poe, M. Horikawa, C. M. Magro, Y. Hamaguchi, K. M. Haas, T. F. Tedder, Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgRI, FcgRIII, and FcgRIV. Blood 112, 1205–1213 (2008).
34. J. Uchida, Y. Hamaguchi, J. A. Oliver, J. V. Ravetch, J. C. Poe, K. M. Haas, T. F. Tedder, The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor–dependent mechanisms during anti-CD20 antibody immunotherapy. J. Exp. Med. 199, 1659–1669 (2004).
35. M. Albanesi, D. A. Mancardi, F. Jönsson, B. Iannascoli, L. Fiette, J. P. Di Santo, C. A. Lowell, P. Bruhns, Neutrophils mediate antibody-induced antitumor effects in mice. Blood 122, 3160–3164 (2013).
36. L. Bevaart, M. J. H. Jansen, M. J. van Vugt, J. S. Verbeek, J. G. J. van de Winkel, J. H. W. Leusen, The high-affinity IgG receptor, FcgRI, plays a central role in antibody therapy of experimental melanoma. Cancer Res. 66, 1261–1264 (2006).
37. M. A. Otten, G. J. van der Bij, S. J. Verbeek, F. Nimmerjahn, J. V. Ravetch, R. H. J. Beelen, J. G. J. van de Winkel, M. van Egmond, Experimental antibody therapy of liver metastases reveals functional redundancy between FcgRI and FcgRIV. J. Immunol. 181, 6829–6836 (2008).
38. N. Gul, L. Babes, K. Siegmund, R. Korthouwer, M. Bögels, R. Braster, G. Vidarsson, T. L. M. ten Hagen, P. Kubes, M. van Egmond, Macrophages eliminate circulating tumor cells after monoclonal antibody therapy. J. Clin. Invest. 124, 812–823 (2014).
39. F. Montalvao, Z. Garcia, S. Celli, B. Breart, J. Deguine, N. Van Rooijen, P. Bousso, The mechanism of anti-CD20–mediated B cell depletion revealed by intravital imaging. J. Clin. Invest. 123, 5098–5103 (2013).
40. T. R. Simpson, F. Li, W. Montalvo-Ortiz, M. A. Sepulveda, K. Bergerhoff, F. Arce, C. Roddie, J. Y. Henry, H. Yagita, J. D. Wolchok, K. S. Peggs, J. V. Ravetch, J. P. Allison, S. A. Quezada, Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma. J. Exp. Med. 210, 1695–1710 (2013).
41. F. Geissmann, M. G. Manz, S. Jung, M. H. Sieweke, M. Merad, K. Ley, Development of monocytes, macrophages, and dendritic cells. Science 327, 656–661 (2010).
42. S. Gordon, The macrophage: Past, present and future. Eur. J. Immunol. 37 (suppl. 1), S9–S17 (2007).
43. M. Haldar, K. M. Murphy, Origin, development, and homeostasis of tissue-resident macrophages. Immunol. Rev. 262, 25–35 (2014).
44. S. Epelman, K. J. Lavine, G. J. Randolph, Origin and functions of tissue macrophages. Immunity 41, 21–35 (2014).
45. C. Schulz, E. Gomez Perdiguero, L. Chorro, H. Szabo-Rogers, N. Cagnard, K. Kierdorf, M. Prinz, B. Wu, S. E. W. Jacobsen, J. W. Pollard, J. Frampton, K. J. Liu, F. Geissmann, A lineage of myeloid cells independent of Myb and hematopoietic stem cells. Science 336, 86–90 (2012).
46. F. Nimmerjahn, A. Lux, H. Albert, M. Woigk, C. Lehmann, D. Dudziak, P. Smith, J. V. Ravetch, FcgRIV deletion reveals its central role for IgG2a and IgG2b activity in vivo. Proc. Natl. Acad. Sci. U.S.A. 107, 19396–19401 (2010).
47. F. Nimmerjahn, J. V. Ravetch, Divergent immunoglobulin G subclass activity through selective Fc receptor binding. Science 310, 1510–1512 (2005).
48. H. Hock, M. J. Hamblen, H. M. Rooke, D. Traver, R. T. Bronson, S. Cameron, S. H. Orkin, Intrinsic requirement for zinc finger transcription factor Gfi-1 in neutrophil differentiation. Immunity 18, 109–120 (2003).
49. T. Hussell, T. J. Bell, Alveolar macrophages: Plasticity in a tissue-specific context. Nat. Rev. Immunol. 14, 81–93 (2014).
50. E. Gomez Perdiguero, K. Klapproth, C. Schulz, K. Busch, E. Azzoni, L. Crozet, H. Garner, C. Trouillet, M. F. de Bruijn, F. Geissmann, H.-R. Rodewald, Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors. Nature 518, 547–551 (2015).
51. R. Ostuni, F. Kratochvill, P. J. Murray, G. Natoli, Macrophages and cancer: From mechanisms to therapeutic implications. Trends Immunol. 36, 229–239 (2015).
52. M. Seeling, U. Hillenhoff, J. P. David, G. Schett, J. Tuckermann, A. Lux, F. Nimmerjahn, Inflammatory monocytes and Fcg receptor IV on osteoclasts are critical for bone destruction during inflammatory arthritis in mice. Proc. Natl. Acad. Sci. U.S.A. 110, 10729–10734 (2013).
53. − monocytes. Nat. Immunol. 12, 778–785 (2011).
54. T. Kurihara, G. Warr, J. Loy, R. Bravo, Defects in macrophage recruitment and host defense in mice lacking the CCR2 chemokine receptor. J. Exp. Med. 186, 1757–1762 (1997).
55. V. Cortez-Retamozo, M. Etzrodt, A. Newton, P. J. Rauch, A. Chudnovskiy, C. Berger, R. J. H. Ryan, Y. Iwamoto, B. Marinelli, R. Gorbatov, R. Forghani, T. I. Novobrantseva, V. Koteliansky, J.-L. Figueiredo, J. W. Chen, D. G. Anderson, M. Nahrendorf, F. K. Swirski, R. Weissleder, M. J. Pittet, Origins of tumor-associated macrophages and neutrophils. Proc. Natl. Acad. Sci. U.S.A. 109, 2491–2496 (2012).
56. M. Guilliams, I. De Kleer, S. Henri, S. Post, L. Vanhoutte, S. De Prijck, K. Deswarte, B. Malissen, H. Hammad, B. N. Lambrecht, Alveolar macrophages develop from fetal monocytes that differentiate into long-lived cells in the first week of life via GM-CSF. J. Exp. Med. 210, 1977–1992 (2013).
57. Q. Gong, Q. Ou, S. Ye, W. P. Lee, J. Cornelius, L. Diehl, W. Y. Lin, Z. Hu, Y. Lu, Y. Chen, Y. Wu, Y. G. Meng, P. Gribling, Z. Lin, K. Nguyen, T. Tran, Y. Zhang, H. Rosen, F. Martin, A. C. Chan, Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J. Immunol. 174, 817–826 (2005).
58. M. Albanesi, D. A. Mancardi, L. E. Macdonald, B. Iannascoli, L. Zitvogel, A. J. Murphy, M. Daëron, J. H. Leusen, P. Bruhns, Cutting edge: FcgRIII (CD16) and FcgRI (CD64) are responsible for anti-glycoprotein 75 monoclonal antibody TA99 therapy for experimental metastatic B16 melanoma. J. Immunol. 189, 5513–5517 (2012).
59. R. Clynes, Y. Takechi, Y. Moroi, A. Houghton, J. V. Ravetch, Fc receptors are required in passive and active immunity to melanoma. Proc. Natl. Acad. Sci. U.S.A. 95, 652–656 (1998).
60. R. A. Clynes, T. L. Towers, L. G. Presta, J. V. Ravetch, Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med. 6, 443–446 (2000).
61. T. Ueno, M. Toi, H. Saji, M. Muta, H. Bando, K. Kuroi, M. Koike, H. Inadera, K. Matsushima, Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin. Cancer Res. 6, 3282–3289 (2000).
62. + monocytes and licenses autoimmunity. Immunity 43, 502–514 (2015).
63. H. Li, M. Ji, K. D. Klarmann, J. R. Keller, Repression of Id2 expression by Gfi-1 is required for B-cell and myeloid development. Blood 116, 1060–1069 (2010).
64. N. Barnes, A. L. Gavin, P. S. Tan, P. Mottram, F. Koentgen, P. M. Hogarth, FcgRI-deficient mice show multiple alterations to inflammatory and immune responses. Immunity 16, 379–389 (2002).